Marco Savarese
banner
marsavarese.bsky.social
Marco Savarese
@marsavarese.bsky.social
Myofin Principal Investigator@Folkhälsan Research Center.
Reposted by Marco Savarese
#RareDiseaseDay is on the last day of February (28th or 29th).

Approximately 5% of the world's population is affected by a rare disease. Rare Disease Day is an important initiative for us, as nearly 90% of neuromuscular disorders are classified as rare diseases. (1/5)
February 28, 2025 at 7:53 AM
Reposted by Marco Savarese
A significant portion of patients with neuromuscular disease remain without a genetic diagnosis, and most neuromuscular disorders still lack a cure. Our work is crucial for providing proper diagnoses and ultimately developing therapies for these patients. (6/6)
February 10, 2025 at 11:47 AM
Reposted by Marco Savarese
While our main interest are neuromuscular disorders caused by mutations in the titin (TTN) and nebulin (NEB) genes, there are many other projects always going on in the group. (5/6)
February 10, 2025 at 11:47 AM
Reposted by Marco Savarese
… to investigate nutrition and self-reported functioning in persons with neuromuscular diseases, and to evaluate therapeutic interventions. (4/6)
February 10, 2025 at 11:47 AM
Reposted by Marco Savarese
Our research aims to identify the genetic variants causing neuromuscular disorders, to understand the normal structure and function of muscle and their alterations in disease, … (3/6)
February 10, 2025 at 11:47 AM
Reposted by Marco Savarese
Our team, led by Dr. Marco Savarese, studies different aspects of hereditary myopathies and muscular dystrophies, continuing the work of the Carina Wallgren-Pettersson and Bjarne Udd groups at FHRC. (2/6)
February 10, 2025 at 11:47 AM
Reposted by Marco Savarese
We are the Myofin Research Group, part of the Genetics Research Program at Folkhälsan Research Center, Helsinki, Finland. (1/6)
February 10, 2025 at 11:47 AM
Reposted by Marco Savarese
Analyzing 145 hard-to-detect variants using HiFi long-read sequencing (LRS), ajhgnews.bsky.social latest article by christiangilissen.bsky.social, ahoischen.bsky.social, & co. highlight LRS as a promising single technology for rare disease diagnosis: www.cell.com/ajhg/abstrac... #ASHG
January 23, 2025 at 8:34 PM